Company / Free Cash Flow
Contineum Therapeutics, Inc. Free Cash Flow History
FY2024-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$33.4M
FY2024
5-year range
-$33.4M / -$33.4M
FY2024-FY2024
Trend
-
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
-$33M in FY2024.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.08 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$33.4M | - |
As of FY2024 · SEC 10-K · Updated Jun 22, 2026